DF/HCC Program Affiliation

Member, Neuro-Oncology Program

DF/HCC Associations

Research Neuropathologist, Neuro Oncology Core
Co-Director, Specialized HistoPathology Core

Research Abstract

My research focuses on the pathology of hereditary brain tumor syndromes, specifically Neurofibromatosis 2 and Tuberous Sclerosis. I am interested in the histopathology of the different lesions encounters in these disease, hamartomas and frank tumors, and on studying how the pathological spectrum correlates with protein expression and mutations of affected genes.

Publications

• Lessell S, Kim JW, Hatton MP, Stemmer-Rachamimov A, Thiagalingham S, Rubin PA. Clinical without histopathological manifestations of inflammation in a patient with primary intraorbital optic nerve sheath meningioma. J Neuroophthalmol 2007 Jun; 27(2):104-6
  PMID: 17548993
• Prabhakar S, Messerli SM, Stemmer-Rachamimov AO, Liu TC, Rabkin S, Martuza R, Breakefield XO. Treatment of Implantable NF2 Schwannoma Tumor Models with Oncolytic Herpes Simplex Virus G47Delta. Cancer Gene Ther 2007 May; 14(5):460-7
  PMID: 17304235
• O'Neill GN, Gonzalez RG, Cros DP, Ackerman RH, Brown RH, Stemmer-Rachamimov A. Case records of the Massachusetts General Hospital. Case 22-2006--a 77-year-old man with a rapidly progressive gait disorder. N Engl J Med 2006 Jul 20; 355(3):296-304
  PMID: 16855271
• Brown AB, Mahmood U, Cortes ML, Tang Y, Dai G, Stemmer-Rachamimov A, Prabhakar S, Leishear K, Onda H, Kwiatkowski D, Weissleder R, Breakefield X. Magnetic resonance imaging and characterization of spontaneous lesions in a transgenic mouse model of tuberous sclerosis as a model for endothelial cell-based transgene delivery. Hum Gene Ther 2005 Dec; 16(12):1367-76
  PMID: 16390268
• Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO, Denko NC, Ligon KL, Rowitch DH, Louis DN. Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma. J Neuropathol Exp Neurol 2005 Nov; 64(11):948-955
  PMID: 16254489
• Nunes F, Shen Y, Niida Y, Beauchamp R, Stemmer-Rachamimov AO, Ramesh V, Gusella J, MacCollin M. Inactivation patterns of NF2 and DAL-1/4.1B (EPB41L3) in sporadic meningioma. Cancer Genet Cytogenet 2005 Oct 15; 162(2):135-9
  PMID: 16213361
• Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res 2005 Mar 15; 11(6):2258-64
  PMID: 15788675
• Stemmer-Rachamimov AO, Nielsen GP, Rosenberg AE, Louis DN, Jones D, Ramesh V, Gusella JF, Jacoby LB. The NF2 gene and merlin protein in human osteosarcomas. Neurogenetics 1998 Dec; 2(1):73-4
  PMID: 9933303
• Stemmer-Rachamimov AO, Ino Y, Lim ZY, Jacoby LB, MacCollin M, Gusella JF, Ramesh V, Louis DN. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 1998 Dec; 57(12):1164-7
  PMID: 9862639
• Stemmer-Rachamimov AO, Xu L, Gonzalez-Agosti C, Burwick JA, Pinney D, Beauchamp R, Jacoby LB, Gusella JF, Ramesh V, Louis DN. Universal absence of merlin, but not other ERM family members, in schwannomas. Am J Pathol 1997 Dec; 151(6):1649-54
  PMID: 9403715